IP Library Granted Patent US 10,124,029
Granted Patent B2
US 10,124,029 · App. 15/342,807 · Granted Nov 13, 2018

Oral compositions and route of administration for the delivery of a thylakoid extract

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,124,029
App. No.
15/342,807
Granted
Nov 13, 2018
Kind
B2
Abstract

A new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Also described is a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Also described is an oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consist of water, physiological saline or propylene glycol. The thylakoid extract or composition is also provided as a food or a food supplement or as a pellet, or encapsulated granules or powder.

Claims (14)

1. An oral composition comprising a purified active thylakoid extract in admixture with an orally-acceptable non-aqueous carrier, wherein the composition, when ingested in a subject, has antioxidant and anti-inflammatory activity.

2. The oral composition of claim 1 , wherein the purified active thylakoid extract is present in an amount between 5 to 1000 mg which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

3. The oral composition of claim 1 , for use in the prevention or treatment of a disease or disorder involving the formation of reactive oxygen species or inflammation.

4. The oral composition of claim 1 , which is a food supplement.

5. The oral composition of claim 4 , wherein the purified active thylakoid extract is present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

6. The oral composition of claim 1 , which is a medication.

7. The oral composition of claim 6 , wherein the purified active thylakoid extract is present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

8. The oral composition of claim 1 , wherein the carrier is present in an amount of 0.01% to 95% (w/w).

9. The oral composition of claim 2 , in the form of a pellet or a capsule.

10. The oral compositions of claim 9 , wherein said pellet or capsule comprises from 200 to 300 mg of purified active thylakoid extract.

11. An oral composition for use in treating a disease or disorder involving the formation of reactive oxygen species or inflammation, the oral composition comprising from 5 to 1000 mg of a purified active thylakoid extract as an active ingredient in admixture with an orally-acceptable non-aqueous carrier.

12. The oral composition of claim 11 , wherein the purified active thylakoid extract is present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject's body weight.

13. The oral composition of claim 11 , in the form of a pellet or a capsule.

14. The oral composition of claim 13 , wherein said pellet or capsule comprises from 200 to 300 mg of purified active thylakoid extract.

Assignments (6)
SECURITY INTEREST Recorded Feb 23, 2024
From: DEVONIAN HEALTH GROUP INC.
To: FIERA PRIVATE DEBT INC.
Reel/Frame 066539/0690 →
RELEASE OF SECURITY INTEREST Recorded Jan 30, 2024
From: GRX HEALTHCARE INC.
To: GROUPE SANTÉ DEVONIAN INC.
Reel/Frame 066287/0652 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REVERSING ASSIGNOR AND ASSIGNEE INFORMATION PREVIOUSLY RECORDED AT REEL: 49895 FRAME: 301. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 30, 2021
From: INVESTISSEMENT QUÉBEC
To: GROUPE SANTÉ DEVONIAN INC.
Reel/Frame 057688/0869 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16154364 PREVIOUSLY RECORDED AT REEL: 048359 FRAME: 0174. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jun 28, 2021
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 057292/0433 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2019
From: GROUPE SANTÉ DEVONIAN INC.
To: INVESTISSEMENT QUÉBEC
Reel/Frame 049895/0301 →
SECURITY INTEREST Recorded Feb 18, 2019
From: DEVONIAN HEALTH GROUP INC.
To: GRX HEALTHCARE INC.
Reel/Frame 048359/0174 →